Canary’s Staked INJ Fund Lists on Nasdaq; Staking Rewards Accrue to NAV, Not Cash Payouts

Canary’s Staked INJ ETF has reached Nasdaq, adding an exchange-traded route to Injective’s native asset. The key distinction is what investors receive: INJC shares provide exposure through a trust holding INJ, while potential staking rewards are reflected in its net asset value rather than paid directly to shareholders.

Three dates, one listing

Nasdaq’s notice dated 4 November specifies a 5 November listing under ticker INJC and names Flow Traders U.S. LLC as designated liquidity provider. Injective’s own launch post is dated 5 November; Canary’s issuer-distributed announcement followed on 6 November. The different publication dates should not turn the listing into a new 7 November event.

The exchange notice establishes the listing arrangements. It does not establish investor inflows, tight spreads or the quantity of INJ purchased because of the launch. NetNapz has not independently reconstructed trading or creation-and-redemption activity.

Staking exposure has a wrapper and a cost

The issuer’s product page says the trust seeks INJ price exposure after expenses, with staking as a secondary objective. It lists a 1.10% sponsor fee, BitGo Bank & Trust as digital-asset custodian and Luganodes as staking provider. These are published product terms, not a performance forecast.

Canary explains that its displayed staked percentage includes assets queued for staking; operational liquidity needs can leave some holdings unstaked. Consequently, a high displayed percentage should not be read as proof that every token is generating rewards at that moment. No current staking yield is asserted here.

Shares are different from directly held tokens

The issuer’s disclosures state that shareholders do not receive the rights of direct INJ holders or individual redemption proceeds in INJ. Shares trade at market prices, which can differ from NAV, and only authorized participants transact directly with the fund in creation units.

The issuer’s prospectus landing-page disclosures state that the product is not registered under the Investment Company Act of 1940 and does not carry the same regulatory requirements as funds registered under that law. Its disclosures identify single-asset volatility and custody risks. Exchange listing therefore should not be interpreted as a guarantee against losses.

NetNapz assessment

The development changes the access route more clearly than it proves new economic demand. Brokerage access can reduce the operational work of buying and managing tokens, but it adds a fund structure, fees and market-price considerations. Whether the wrapper attracts durable demand requires subsequent evidence.

Useful follow-up measures include dated net creations, trading spreads, tracking against NAV and realized staking results after costs. Those measures answer different questions: secondary-market turnover is not automatically a net inflow, and a staking objective is not a promised distribution. This report makes no claim that the listing caused an INJ price move.

Sources and verification limits

Nasdaq’s listing notice, Injective’s 5 November announcement, Canary’s 6 November release, product terms and brand permissions were checked on 7 November. The issuer page contains separately dated data fields; none is presented as a live market quote. The prospectus landing page was retrieved, but a complete final prospectus document was not independently reviewed. Published site coverage was checked for duplication. NetNapz did not audit custody, validator performance or fund accounting. Reporting and assessment are separated above; this is not investment advice.